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Available online 30 April 2013Abstract Recent evidence has shown that bone marrow stromal cells (BMSCs) may exhibit immuno-suppression activities
through soluble mediators and direct cell–cell contact, but how these processes are modulated has been poorly understood.
In this study, we show that the Notch signaling pathway participates in the modulation of BMSCs to elicit their
immuno-suppressive roles. In a murine lethal acute graft versus host disease (aGvHD) model, BMSCs deficient for RBP-J, the
critical transcription factor mediating signaling from all four mammalian Notch receptors, failed to delay the development of
the disease. RBP-J deficient BMSCs were not able to inhibit the proliferation and activation of allogenic T-cells. Moreover,
RBP-J deficient BMSCs could not down-regulate the expression of MHC II and co-stimulation molecules CD80 and CD86 on
dendritic cells (DCs). The antigen presentation capacity of DCs co-cultured with RBP-J deficient BMSCs was not impaired in
contrast to wild type BMSCs. Furthermore, we showed that the productions of IL-6 and PGE2, two critical molecules mediating
the immuno-suppressive activities of BMSCs, were reduced significantly in RBP-J deficient BMSCs. Both of the two molecules
were importantly involved in the regulation of BMSCs by Notch signaling. In conclusion, our data suggests that the
immuno-suppressive effects of BMSCs in aGvHD are dependent on Notch-RBP-J signaling, which regulates the productions of
IL-6 and PGE2.
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Bone marrow stromal cells (BMSCs) consist of a heteroge-
neous population of cells that provide the structural and
functional support for hematopoietic cells (Bianco et al.,
2001; Sacchetti et al, 2007). These cells have fibroblast-like
morphology, express CD29, CD44, CD73, CD90, CD105 and
CD166, and are negative for CD14, CD34, and CD45 (Boxall
722 Y.-C. Wang et al.and Jones, 2012). Additionally, BSMC populations contain a
sub-population of stem cells with the ability to differentiate
into cartilage, bone, stroma that supports hematopoiesis,
and marrow adipocytes (Spencer et al., 2011).
Although inconsistency exists, recent evidence has shown
that BMSCs can inhibit immune responses in different
experimental and clinical settings through suppressing both
innate and adaptive immune cells, such as natural killer (NK)
cells, dendritic cells (DCs), B-cells, and T-cells (Yagi et al.,
2010). For example, Bartholomew et al. showed that systemic
administration of autologous or allogeneic BMSCs increased
the viability of allogeneic skin grafts in baboons (Bartholomew
et al., 2002). In graft-versus-host disease (GvHD), transfusion
of BMSCs has been shown to attenuate the disease (Le Blanc et
al., 2004, 2008; Miyake et al., 2008). It has been further shown
that BMSCs can suppress T-cell activation through cell–cell
contacts and various soluble factors including transforming
growth factor (TGF)-β1, hepatocyte growth factor (HGF),
indoleamine 2,3-dioxygenase and prostaglandin (PG) E2,
among others (Trento and Dazzi, 2010; Glennie et al., 2005;
Le Blanc et al., 2003). Moreover, BMSCs can inhibit the
maturation and function of monocyte-derived DCs, likely by
the production of interleukin (IL)-6, monocyte-colony stimu-
lating factor (M-CSF), and PGE2 (Spaggiari et al., 2009; Jung et
al., 2007; Kronsteiner et al., 2011; Djouad et al, 2007; Nauta
et al., 2006; Zhang et al., 2009). However, while the immuno-
suppressive functions of BMSCs upon systemic infusion remain
to be definitively demonstrated in vivo, how these roles of
BMSCs are modulated has not been fully elucidated.
Notch signaling mediates direct cell–cell communications
that are essential for the proliferation and differentiation of
stem/progenitor cells (Artavanis-Tsakonas et al., 1999). In
mammals, there are five Notch ligands (Delta-like [Dll] 1, 3, 4,
and Jagged 1, 2) and four Notch receptors (Notch 1–4). The
transcription factor RBP-J (recombination signal binding
protein-Jк) mediates signaling from all four Notch receptors
by associating with the Notch intracellular domain (NIC),
which is released from the membrane by a γ-secretase-
mediated proteolytic mechanism upon receptor triggering.
Transactivated RBP-J further regulates cell proliferation and
differentiation by modulating downstream gene expression.
It has been shown that RBP-J-dependent Notch signaling
regulates mesenchymal progenitor cell proliferation and
differentiation during skeletal development (Dong et al.,
2010). It was also suggested that Notch signaling played
an important role during MSC-mediated inhibition of the
differentiation of monocytes into DCs (Li et al., 2008b). In
this study, by using a mouse acute GvHD (aGvHD) model, we
show that the immuno-suppressive function of BMSCs in
aGvHD is dependent on Notch signaling, and that Notch
signaling regulates the immune-suppression of BMSCs
through the production of IL-6 and PGE2.Materials and methods
Animals
Inbred C57BL/6 (H2b) and BALB/c (H2d) female mice were
raised in the specific pathogen free (SPF) conditions. The
animal husbandry, experiments and welfare were conducted
in accordance with the Detailed Rules for the Administrationof Animal Experiments for Medical Research Purposes issued
by the Ministry of Health of China, and were approved by the
Animal Experiment Administration Committee of Fourth
Military Medical University. The Mxl-Cre (MxCre) transgenic
mouse strain (Kuhn et al., 1995) was provided by K Rajewski,
and the RBP-J-floxed mouse (RBP-Jf) has been maintained
in our lab (Han et al., 2002). The Cre-mediated deletion
of the floxed RBP-J exons was induced in 1-month-old
RBP-Jf/f-MxCre and RBP-J+/f-MxCre mice by using poly(I)–
poly(C) (Sigma, St. Louis, MO) as described (Han et al., 2002).
Culture of murine BMSCs
BMSCs from murine compact bones were isolated and cultured
as described previously (Zhang et al., 2009). Briefly,micewere
euthanized according the rules of the Association for Assess-
ment and Accreditation of Laboratory Animal Care (AAALAC).
BM was flushed from femurs and tibias, and single-cell
suspension was obtained by passing through an 18-gage
needle and filtered with a nylon membrane, followed by
erythrolysis in buffered 0.14 M NH4Cl. Cells were counted and
cultured in 6-well plates in DF12 medium (Invitrogen,
Carlsbad, CA) containing 20% fetal calf serum (FCS) and 2 mM
L-glutamine in a humidified atmosphere of 5% CO2 at 37 °C.
Adherent cells were passaged routinely at 4 day intervals, and
cells at passages 3–5 were used. BMSCs were treated with
50 μg/ml mitomycin C (MMC, Sigma, St. Louis, MI) at 37 °C for
45 min followed by five extensive washes with cold PBS before
further experiments.
DC culture
DCs were cultured as described previously (Wang et al., 2009).
Briefly, nucleated BM cells (2 × 106) were counted and cultured
in 24-well plates in 1 ml of RPMI1640 medium containing 20%
FCS and 2 mM L-glutamine, and supplemented with 20 ng/ml
mouse GM-CSF and 10 ng/ml mouse IL-4 (Pepro Tech, Inc.) for
9 days. Bacterial lipopolysaccharide (LPS, 1 μg/ml, Sigma) was
added to the culture for 12 h to stimulate DC maturation. For
transwell cultures, DCs (2 × 105) were seeded into the upper
chamber (with 0.4-μm pore size, Costar) in a volume of 100 μl
of RPMI1640 supplemented with 1% bovine serum albumin
(BSA). BMSCs (4 × 104/well) were plated in the lower chamber
in 600 μl of RPMI1640. In some experiments, IL-6 (PeproTech,
Rocky Hill, NJ) or an anti-IL-6 antibody (R&D Systems,
Minneapolis, MN) was applied in the culture.
Flow cytometry
Single cell suspensions were prepared from cultured cells or
tissues, followed by treatment with buffered 0.14 M NH4Cl if
necessary. Cells (3 × 105) were stained with antibodies for
30 min on ice, andwere analyzed by using a FACSCalibur™ flow
cytometer (BD Immunocytometry Systems, San Jose, CA).
Data were analyzed with the CellQuest™ software. Dead cells
were excluded by propidium iodide (PI) staining. Biotinylated
anti-mouse CCR7 was purchased from eBioscience (San Diego,
CA). Biotinylated anti-mouse I-Ab (KH174), anti-mouse CD3-
APC (17A2), anti-mouse CD4-APC (L3T4), anti-mouse CD8-APC
(53-6.7), anti-mouse CD69-FITC (H1.2F3), anti-mouse CD80-
FITC (16-10A1), anti-mouse CD86-PE (GL-1), anti-mouse-
723Notch-RBP-J signaling for the treatment of acute graft versus host diseaseCD11c-FITC (N418) and anti-mouse-CD11c-PE (HL3) were from
BD PharMingen (San Diego, CA). For cytoplasmic staining, cells
were treated with Brefeldin A and were stained and analyzed
by using a Fixation & Permeabilization Kit (eBioscience)
following the recommended protocols.
Murine aGvHD model
Murine aGvHD model was established as described (Schroeder
and DiPersio, 2011). Briefly, splenic and BMmononuclear cells
were prepared from female C57BL/6 mice. Splenocytes
(2 × 107) and BM cells (1 × 107) were injected intravenously
(i.v.) into lethally irradiated (950 cGy of γ-ray) female BALB/c
mice. BMSCs from BALB/c were infused via two injections
with an interval of 1 h, with the first injection performed
simultaneously with the splenocytes. Each injection con-
tained 1 × 106 BMSCs in 0.2 ml of phosphate-buffered saline
(PBS), a procedure that has been reported to increase the
pulmonary passage of BMSCs (Fischer et al., 2009). On days
2, 4, and 6 after the transplantation, the spleens, lymph
nodes and colon of the recipient mice were harvested and
analyzed.
Histology
Tissues from the aGvHDmice were taken for pathologic analysis
on day 6 after transplantation. Specimens of the liver, spleen,
gut, and lung were fixed in 4% paraformaldehyde, embedded in
paraffin, sectioned at 10 μm thickness, and stained with
hematoxylin and eosin (H&E) by standard methods.
Mixed lymphocyte reaction
Splenic T-cells were obtained from C57BL/6 mice by negative
selection with magnetic beads (Miltenyi Biotec GmbH,
Bergisch Gladbach, Germany) and loaded with CFSE. BMSCs
were preplated in 96-well plates (5 × 104/well) and irradiated
with 20 Gy of γ-ray 24 h after the plating. T-cells (2 × 105/
well) were cultured with irradiated (20 Gy) BALB/c splenic
mononuclear cells at a ratio of 1:50, in the absence or
presence of BMSCs. The cultures were incubated in a total
volume of 200 μl/well of medium. Five days later, cells were
collected for the analysis of proliferation and expression of
CD69 or IFN-γ by FACS.
Antigen uptake assay
Antigen uptake was measured by using FITC-dextran (1 mg/ml;
molecular weight 40,000; Sigma). Approximately 5 × 105 cells
were incubated inmedium containing FITC-dextran for 60 min.
The cells were then washed twice with cold PBS. The quan-
titative uptake of FITC-dextran by the cells was determined by
FACS.
Antigen presentation assay
C57BL/6 mice were immunized by injection intraperitone-
ally (i.p.) with 100 mg ovalbumin (OVA) mixed with
complete Freund's adjuvant (CFA), and strengthened 7 days
later with the same dose of antigen. Fifteen days after theprimary immunization, T-cells were isolated from the lymph
nodes through negative selection by using the Pan T-Cell
Isolation Kit II (Miltenyi). Syngeneic DCs were pulsed with
OVA (10 μg/ml) for 12 h, and then co-cultured with
OVA-specific T-cells pre-loaded with CFSE (Molecular
Probes) at the ratio of 1:10 for 5 days. The proliferation of
CD4+ and CD8+ OVA-specific T-cells was detected by FACS.
The CD3+ T-cells were sorted by magnetic beads, and the
expressions of CD69 and IFN-γ were examined by FACS.
For in vivo assay, C57BL/6 mice were immunized with OVA
by standard procedures. BM cells from GFP transgenic C57BL/
6 mice were induced into DCs in the presence of BMSCs. Cells
were trypsinized, and DCs were isolated by using anti-CD11c
magnetic beads (Miltenyi). These GFP-DCs (5 × 105) were
then pulsed with OVA for 12 h, and injected subcutaneously
(s.c.) at the left hind footpads of the OVA-immunized mice.
Meanwhile, BrdU (0.6 mg) was injected i.p. every 6 h.
Draining lymph nodes were harvested 3 days later, and the
proliferation of CD3+ T-cells was detected by staining with
FITC-labeled anti-BrdU antibody (Sigma), followed by FACS.
The expressions of CD69 and IFN-γ by CD3+ T-cells were also
examined by FACS.
To detect the influence of BMSCs on mature DCs in vivo,
GFP-DCs (5 × 105) culturedwithout BMSCswere injected s.c. at
the left hind footpads of OVA-immunized mice, and then
2 × 106 BMSCs were injected i.v. 15 min later via two
injections as described above. Mice were observed as above.
In vivo allo-delayed type hypersensitivity (DTH) assay
Allo-DTH was performed as reported previously (Zhang et al.,
2009). Briefly, BALB/c mice were immunized on the dorsal
trunk by inoculation s.c. with C57BL/6 splenocytes (108 cells/
mouse), and re-challenged 7 and 14 days later at the hind
footpads by injecting the same cells (108 cells/mouse). DCs
(3 × 106 cells/mouse) from C57BL/6 mice were injected i.p.
on days −6, −4, 0, 3, and 6. Footpad thickness was measured
on days 8 and 15 with a caliper-type engineer's micrometer by
a third experimenter who is blind of the sample identity. The
extent of swelling was calculated as the thickness of the right
footpad (receiving C57BL/6 splenocytes) minus the baseline
thickness of the left footpad (receiving BALB/C splenocytes).
Reverse transcription-polymerase chain reaction
(RT-PCR)
Total RNA was prepared from cultured cells and reverse-
transcribed to generate cDNA. Real-time PCR was performed by
using a kit (SYBR Premix EX Taq, Takara) and the ABI PRISM 7500
Real-time PCR system. Primers used in real-time PCR were as
follows: IL-6 (NM031168): 5′CTCTGGGAAATCGTGGAAATG and
AAGTGCATCATCGTTGTTCATACA; β-actin (NM007393): 5′CATC
CGTAAAGACCTCTATGCCAAC and 5′-ATGGAGCCACCGATCCACA.
Western blot
Whole cell extracts were prepared by lysing cells with the RIPA
buffer (50 mM Tris–HCl, pH 7.9, 150 mM NaCl, 0.5 mM EDTA,
and 0.5% Nonidet P-40, 0.1 mMphenylmethylsulfonyl fluoride).
Proteins were separated by SDS-PAGE with 12% polyacryl-
amide, and electroblotted onto polyvinylidene difluoride
724 Y.-C. Wang et al.(PVDF) membrane. Membranes were probed by using rabbit-
anti-mouse P-Stat3, Stat3, P-Akt and Akt (Thermo Fisher
Scientific, Fremont, CA), and monoclonal anti-β-actin (AC-74,
Sigma) at appropriate dilutions, followed by incubation withhorseradish peroxidase-conjugated secondary anti-rabbit or
anti-mouse IgG antibody (Sigma). Blots were developed by
using an enhanced chemiluminescence system (Roche Applied
Science).
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The culture supernatants were collected, and were used to
detect cytokines and PGE2 by using different assay kits
(Jinmei Biotec, Shen Zhen, China). OD450 was recorded using
a spectrophotometer.Statistics
The statistical analysis was performed with the SPSS 12.0
program. Results were expressed as the means ± SD. The
comparisons between groups were undertaken using the
unpaired Student's t-test. P b 0.05 was considered statisti-
cally significant.Results
BMSCs from RBP-J knockout mice failed to delay
lethal aGvHD in vivo
To examine the role of Notch signaling in BMSCs, we employed
homozygous RBP-J-floxed mice bearing Mx1-Cre transgene
(RBP-J−/−), with heterozygous mice bearing Mx1-Cre (RBP-
J+/−) as controls (Han et al., 2002). Injection of poly(I)–poly(C)
induced almost complete deletion of the floxed RBP-J exons in
BMSCs (Xie et al., 2013). No significant difference in cell
proliferation or apoptosis was detected between RBP-J−/− and
RBP-J+/− BMSCs (data not shown). The wild type, RBP-J+/− and
RBP-J−/− BMSCs expressed similar levels of CD29, CD44, CD90,
CD106 and Sca-1, and did not express F4/80, CD11b, CD34,
CD45, CD117 or MHC II (supplementary Fig. S1). The secretion of
IL-8, TGF-β, matrix metalloproteinase (MMP)-2, -9, and
thrombospondin (TSP)-1 was comparable between the RBP-J
deficient and control BMSCs. The expressions of VEGF, IL-6, and
PGE2 were reduced when Notch signaling was blocked
(supplementary Fig. S2).
To determine the roles of Notch signaling in BMSCs to
regulate the development of lethal aGvHD, spleen and BM
mononuclear cells derived from C57BL/6 were injected i.v.
into lethally irradiated BALB/c mice, with or without BMSCs
of different genotypes injected simultaneously. Because
previous reports have shown that intravenously injected
BMSCs are initially trapped in the lung (Lee et al., 2009;
Fischer et al., 2009), the distribution of BMSCs after
intravenous injection in aGvHD mice was analyzed firstly
(supplementary Fig. S3). While many of the injected BMSCs
were trapped in the lung, a substantial fraction of cells could
be found in the spleens and other organs of the recipient
mice 2 days after the injection. The result showed thatFigure 1 BMSCs without RBP-J failed to inhibit aGvHD in mice. (A
mononuclear cells (1 × 107) from C57BL/6 mice were injected i.v. in
together with 2 × 106 different BMSCs via two equal injections (1 ×
mice was compared on different days after cell infusion. (B) The pho
(C) Lungs, livers, and colons from different groups of mice in (B) wer
(D) Sera from the mice in (B) were collected and were measured for t
prepared from the spleen, lymph nodes and colons of the mice in (B
shown in supplementary Fig. S4). Absolute number of I-Ab+CD3+ cells
between groups. Bars = means ± SD. *, P b 0.05, n = 6.while RBP-J+/− BMSCs (BMSCs+/−) significantly prolonged the
survival of aGvHD mice, RBP-J−/− BMSCs (BMSCs−/−) failed to
do so (Fig. 1A). Both aGvHD mice without cell therapy and
treated with BMSCs−/− showed ruffled fur, a representative
symptom of aGvHD (Le Blanc et al., 2004), which was
alleviated significantly by the BMSCs+/− injection (Fig. 1B).
Histological examination of livers, lungs, and colons, three
target organs of aGvHD, showed heavy lymphocyte infiltration
in mice without cell therapy (Fig. 1C). Although treatment
with BMSCs+/− remarkably reduced cell infiltration, BMSCs−/−
showed no therapeutic effect on cell infiltration in liver, lung,
or colon in the aGvHD mice. Examination of serum inflamma-
tory cytokines including IL-6, IL-12, TNF-α and IFN-γ showed
that infusion of BMSCs+/− strongly reduced cytokine levels
compared with the group without cell therapy, but mice
treated with BMSCs−/− exhibited similar cytokine levels with
the group without cell therapy (Fig. 1D).
BMSCs can enhance donor-derived CD3+ cells to homing to
secondary lymphoid organs in aGvHD (Li et al., 2008a;
Hasegawa et al., 2000). We therefore examined donor-
derived CD3+ cell distribution in the recipient mice during
aGvHD. Compared with the aGvHD mice without cell therapy,
infusion of BMSCs+/− significantly increased donor-derived
CD3+ cells in spleens and lymph nodes of the recipient mice.
However in aGvHD mice accepting BMSCs−/−, donor-derived
CD3+ cells in the secondary lymphoid organs were at the
similar level as in aGvHD mice without cell therapy (Fig. 1E,
supplementary Fig. S4). In contrast, BMSCs+/− reduced the
homing of donor-derived CD3+ cells in colon, but infusion of
BMSCs−/− cells did not influence the homing of donor-derived
CD3+ cells in the colon of aGvHDmice (Fig. 1E, supplementary
Fig. S4). These data suggested that RBP-J dependent Notch
signaling was required for BMSCs to exert their immune-
regulatory roles in aGvHD.RBP-J KO canceled the suppression of T-cell activation
by BMSCs in vitro
BMSCs efficiently suppress the proliferation and activation of
T-cells (Tse et al., 2003; Di Nicola et al., 2002). To examine the
role of Notch signaling in this process, we performed MLR in the
presence of BMSCs+/− or BMSCs−/−. Spleen T-cells from C57BL/
6 mice were loaded with CFSE and cultured with irradiated
spleen monocytes from BALB/c mice, in the presence of
irradiated BMSCs+/− or BMSCs−/− for 5 days. The proliferation
of T-cells was inhibited significantly by BMSCs+/− compared
with the culture without BMSCs. BMSCs−/−, in contrast, failed
to inhibit T-cell proliferation in MLR (Figs. 2A, B). The
expressions of CD69 and IFN-γ, two T-cell activation markers,
were similarly down-regulated in the presence of BMSCs+/− but) Survival of different groups of mice. Splenic (2 × 107) and BM
to lethally irradiated (950 cGy of γ-ray) BALB/c mice without or
106 cells each interval of 1 h) in 0.2 ml of PBS. The survival of
tographs of mice in different groups on day 6 after cell infusion.
e sectioned and stained with H&E (original magnification ×400).
he indicated cytokines by ELISA. (E) Single cell suspensions were
), and I-Ab+CD3+ cells were analyzed by FACS (FACS data were
in each organ was calculated on days 2, 4 and 6, and compared
Figure 2 RBP-J deficient BMSCs failed to inhibit T-cell proliferation and activation in vitro. (A, C, E) Mixed lymphocyte reaction.
C57BL/6 BMSCs with the indicated genotypes were seeded in 96-well plates and were irradiated. CFSE-loaded syngeneic T-cells were
cultured with irradiated BALB/c splenic mononuclear cells in the absence or presence of BMSCs at a ratio of 1:50. On day 5 after
incubation, CD3+ cells were collected for FACS analysis of CFSE (A), CD69 (C), and IFN-γ (E). (B, D, F) Absolute numbers of
proliferating cells (B) and CD69+ (D) and IFN-γ+ (F) were calculated and compared between groups. Bars = means ± SD. *, P b 0.05,
n = 6.
726 Y.-C. Wang et al.not BMSCs−/− (Figs. 2C–F). These data indicated that BMSCs
suppressed T-cell activation in a RBP-J dependent way.RBP-J deficient BMSCs could not block thematuration
of DCs
BM monocytes were induced to differentiate into DCs by
culturing in the presence of GM-CSF and IL-4 (Wang et al.,
2009). DCs were stimulated with LPS to induce maturation in
the presence of BMSCs+/− or BMSCs−/−. The result showed thatFigure 3 RBP-J deficient BMSCs could not inhibit DC maturation. (
absence or presence of BMSCs with different genotypes, and the e
CD86 and MHC II were analyzed by FACS. Mean fluorescence inten
(C, D) The same experiment was performed as in (A) by using a tr
separately in the upper and lower chambers, respectively. (E, F) The
FACS and MFI of these markers were compared between groups. (G,
1 mg/ml FITC-dextran for 60 min. Cells were then washed twice with
between groups. (I) Cytokine production. DCs in (A) were collected b
and cultured for 5 days. Supernatants were collected and measu
*, P b 0.05, n = 6.BMSCs+/− significantly down-regulated the expression of CD80,
CD86 and MHC II, suggesting that the maturation of DCs was
suppressed by BMSCs+/−. BMSCs−/−, in contrast, failed to down-
regulate the expression of these molecules (Figs. 3A and B).
These effects of the RBP-J deficient and control BMSCs on DC
maturation were mediated by secretary factors, because
similar phenomena were found in a transwell culture system
in which DCs did not contact with BMSCs (Figs. 3C and D). We
also examined the expression of chemokine receptors on DCs
(Hasegawa et al., 2000). The result showed that co-culture of
DCs with BMSCs+/− but not BMSCs−/− down-regulated theA, B) BM monocyte-derived DCs were stimulated with LPS in the
xpressions of CD11c and costimulatory markers including CD80,
sities (MFI) of these markers were compared between groups.
answell culture system in which DCs and BMSCs were cultured
expressions of CCR7 and CXCR4 on DCs in (A) were examined by
H) DCs in different groups were incubated in medium containing
cold PBS, and analyzed by FACS. MFI of dextran were compared
y CD11c magnetic beads. The cells were seeded in 96-well plates
red by ELISA for the indicated cytokines. Bars = means ± SD.
727Notch-RBP-J signaling for the treatment of acute graft versus host diseaseexpression of CCR7 and CXCR4 on DCs (Figs. 3E and F).
Moreover, by using FITC-conjugated Dextran, we found that
BMSCs−/−-treated DCs showed lower antigen uptake capacity,but BMSCs+/−-treated DCs showed normal antigen uptake
capacity compared with the controls (Figs. 3G and H). The
cytokine expression pattern of DCs treated with different
728 Y.-C. Wang et al.BMSCs was determined by ELISA. The result showed that the
control BMSCs (BMSCs+/+ and BMSCs+/−) significantly
suppressed IL-12 and TNF-α production while increased
IL-10 production by DCs, but these roles were canceled
upon RBP-J deletion in BMSCs (Fig. 3I). These results
indicated that while BMSCs could block DC maturation,
RBP-J deficiency abrogated this effect of BMSCs.
RBP-J deficiency abrogated the ability of BMSCs to inhibit
antigen presentation by DCs
To investigate whether RBP-J deficient BMSCs could block
DC-mediated activation of T-cells, antigen presentation assays
were performed. T-cells were isolated from lymph nodes of
C57BL/6 mice immunized with OVA and loaded with CFSE.
Syngeneic DCs were co-cultured with BMSCs+/− or BMSCs−/−
while being loaded with the OVA antigen. After being isolated
by using CD11c magnetic beads, the DCs and T-cells were then
co-cultured, and the proliferation and activation markers
expression of T-cells were examined. The results showed that
while antigen-specific DCs co-cultured with BMSCs+/− strongly
inhibited the proliferation of CD4+ and CD8+ T-cells, DCs
co-cultured with RBP-J deficient BMSCs (BMSCs−/−) maintained
normal ability to stimulate the proliferation of antigen-specific
T-cells (Figs. 4A, D). Similarly, T-cells stimulated with DCs
co-cultured with BMSCs+/− expressed low level of T-cell
activation markers CD69 and IFN-γ, but T-cells stimulated
with DCs co-cultured with BMSCs−/− expressed normal level of
these molecules (Figs. 4B–D). These results suggested that
BMSCs without Notch signaling were deprived of the ability to
interrupt the antigen presentation activity of DCs.BMSCs without RBP-J could not inhibit DCs to prime
T-cells in vivo
To examine the effects of RBP-J deficient BMSCs on immune
responses in vivo, we employed two experiments. First, C57BL/
6 mice were pre-immunized with OVA, and re-challenged
at footpads with OVA-loaded DCs pre-co-cultured with BMSCs
of different genotypes (BMSC-precultured). In the second
experiment, C57BL/6 mice pre-immunized with OVA were re-
challengedwithOVA-loadedDCs at footpads, followed by BMSCs
injection i.v. 3 h after DC inoculation (BMSC-injected) (Chiesa
et al., 2011). Three days after DC re-challenge, the draining
lymph nodes of the mice were isolated and analyzed. The
results showed that in both models, compared with mice
treated with BMSCs+/−, the number of CD3+ T-cells increased
remarkably in draining lymph nodes of mice treated with
BMSCs−/− (Fig. 5A). The proliferation of CD3+ T-cells was
observed by using BrdU incorporation, and the result
showed that the mice treated with BMSCs−/− showed
significantly higher rate of T-cell proliferation in draining
lymph nodes than the BMSCs+/−-treated mice (Figs. 5B, C).
By using GFP+ DCs, we found that about 3-fold more DCs wereFigure 4 RBP-J knockout BMSCs failed to suppress antigen spec
immunized with OVA for 15 days. Syngeneic DCs pulsed with OVA we
in the absence or presence of different BMSCs. The proliferation of C
The expressions of CD69 (B) and IFN-γ (C) in OVA-specific T-cells in
selection with magnetic beads. (D) Absolute numbers of the positive
Bars = means ± SD. *, P b 0.05, n = 6.homed in draining lymph nodes in BMSCs−/−-treated groups than
the controls (Figs. 5D, E). Furthermore, in the BMSCs−/−-treated
mice, T-cells in the draining lymph nodes expressed higher
levels of CD69 and IFN-γ than the BMSCs+/−-treated groups
(Figs. 5F–I). These data suggested that RBP-J deficient BMSCs
were weaker in suppressing immune responses in vivo as
compared with normal BMSCs.
We next examined the effect of different BMSCs on DCs in
an allo-DTH immune reaction in vivo. DCs were pre-cultured
with BMSCs with different genotypes, and were injected i.p.
into mice suffering from allo-DTH. The result showed that
while pre-culture with wild-type or RBP-J+/− BMSCs signifi-
cantly repressed footpad swelling of BALB/c mice receiving
the alloantigen, pre-culture with BMSCs−/− failed to do so
(Fig. 5J). These results further suggested that disruption of
RBP-J abrogated the suppressive effects of BMSCs on
immune responses.IL-6 and PGE2 regulated by Notch signaling played
an important role in the differentiation of DCs
IL-6 induces an inhibitory signal for DC maturation through
triggering the activation of Stat3 (Park et al., 2004). An RBP-J-
binding site was identified in the IL-6 promoter to regulate the
expression of IL-6 (Palmieri et al., 1999). IL-6 was measured in
the supernatant of different BMSC cultures by using ELISA.
Compared with BMSCs+/−, BMSCs−/− produced significantly
lower level of IL-6 (Fig. 6A). When BMSCs+/− cells were
co-cultured with BMmonocytes (BMM) (Spaggiari et al., 2009),
IL-6 level in the supernatant increased significantly. The level
of IL-6 was still high when BMM was removed from the
co-culture system, indicating that IL-6 was mainly secreted by
BMSCs. In the case of BMSCs−/−, in contrast, the basal IL-6
level and the IL-6 level in the presence of BMM decreased
significantly. We also examined IL-6 mRNA levels of BMSCs in
the presence or absence of BMM. IL-6 mRNA expression
was significantly lower in MSC−/− than in BMSCs+/− (Fig. 6B).
Binding of IL-6 to its receptor initiates cellular events
including activation of Stat3 signaling and activation of Akt
(Park et al., 2004). DCs cultured with different BMSCs for
5 days were isolated by using CD11c magnetic beads and
analyzed for the phosphorylation of Stat3 and Akt by Western
blot. DCs co-cultured with BMSCs−/− showed significantly
lower Stat3 or Akt phosphorylation than DCs co-cultured with
BMSCs+/− (Fig. 6C). These results suggested that the Notch
signaling may regulate the expression of IL-6 in BMSCs to
regulate DCmaturation. Consistently, addition of IL-6 into the
co-culture of BMSCs−/− and DCs reduced the expression of
CD80, CD86, and MHC II by DCs, to a similar level to that of the
BMSCs+/− co-culture (Figs. 6D and E). On the other hand,
inclusion of anti-IL-6 to the co-culture of BMSCs+/− and DCs
enhanced the expression of CD80, CD86 and MHC-II by DCs
(Figs. 6D and E).ific T-cell activation by DCs in vitro. (A) C57BL/6 mice were
re co-cultured with OVA-specific CFSE-labeled T-cells for 5 days,
D4+ and CD8+ OVA-specific T-cells was detected by FACS. (B, C)
(A) were examined after CD3+ T-cells were isolated by positive
cells in (A–C) were calculated and compared between groups.
729Notch-RBP-J signaling for the treatment of acute graft versus host disease
730 Y.-C. Wang et al.
731Notch-RBP-J signaling for the treatment of acute graft versus host diseaseBMSCs regulate DC maturation through the production of
PGE2. PGE2 could also be an important mediator for the
BMSC-mediated suppression of T-cell proliferation (supplemen-
tary Fig. S5). Disruption of RBP-J in BMSCs remarkably reduced
PGE2 production, regardless of the absence or presence of
BMM (Fig. 6F). Treatment of BMSCs+/− with anti-IL-6 reduced
PGE2 production, while treatment of BMSCs−/− cells with IL-6
increased PGE2 production (Fig. 6F), suggesting that RBP-J-
mediated signaling regulated PGE2 production by BMSCs.Discussion
BMSCs regulate immune responses by interactions with a
wide range of immune cells through direct cell–cell contacts
and soluble factors. This property of BMSCs has been
translated into potential therapies for human diseases such
as aGvHD (Palmieri et al., 1999). In this study, we show that
the immuno-regulation function of BMSCs is under the control
of Notch signaling. As far as we have tested, Notch signaling
may modulate BMSC-mediated immuno-suppression through
at least two types of cells, T-cells and DCs. BMSC infusion may
lead to altered migration of T-cells and DCs in the secondary
lymphoid organs and disease-targeted organs of aGvHDmice,
contributing to immuno-suppression (Korngold and Sprent,
1985; Weng et al., 2010; Aggarwal and Pittenger, 2005; Viola
et al., 2006). This role of BMSCs was canceled upon RBP-J
disruption. Also, RBP-J deficient BMSCs failed to inhibit the
proliferation of T-cells that is critical for BMSCs to suppress
T-cell activation (Glennie et al., 2005). Moreover, RBP-J
deficient BMSCs were not able to block DC maturation,
therefore failed to abrogate DC-mediated T-cell activation.
This might also play a critical role in the attenuation of
immuno-suppression activity of BMSCs by RBP-J disruption.
Giving the critical role of RBP-J in mediating canonical Notch
signaling (Artavanis-Tsakonas et al., 1999), our data suggest
that RBP-J-mediated Notch signaling participates in the
regulation of the immuno-suppression roles of BMSCs.
Many studies (Lee et al., 2009; Fischer et al., 2009) have
reported that intravenously injected BMSCs are initially trapped
in the lung. However, it has also been shown that pulmonary
trapping of infused cells may be a transient phenomenon.
Intravenously injected BMSCs or peripheral blood stem cells
(PBSCs) accumulate initially in the lung when observed in an
hour after injection (Gao et al., 2001; Daldrup-Link et al., 2004;
Schrepfer et al., 2007), and redistribute to liver, spleen, kidney
and BM 48 h later (Gao et al., 2001; Daldrup-Link et al., 2004).Figure 5 BMSCs without RBP-J did not suppress DCs in inducing imm
prepared from BM monocytes of GFP transgenic mice (C57BL/6). C5
GFP+ DCs were pre-cultured with BMSCs of the indicated genotypes
OVA-immunized mice (BMSC-pre-cultured). In another experiment,
OVA-immunized mice, and then BMSCs were injected i.v. (BMSC-tre
CD3+ cells in lymph nodes were compared. (B, C) After DCs were inje
draining lymph nodes were analyzed for BrdU by FACS. (D, E) GFP+
(F, G) The expressions of CD69 in CD3+ T-cells of draining lymph node
T-cells of draining lymph nodes were examined by FACS. (J) DTH
inoculation s.c. of C57BL/6 splenocytes on day 0 and challenged o
antigens. DCs from C57BL/6 mice were pre-cultured with PBS or BM
Footpad thickness was measured on days 8 and 15. The extent of
(receiving C57BL/6 splenocytes) minus the baseline thickness of theRochefort et al. found a 50–60% pulmonary accumulation of
BMSCs 1 h after infusion and this percentage went down to
about 30% 3 h post injection (Rochefort et al., 2005). Kang et al.
reported that intravenous injection of PBSCs had a high lung
uptake at 30 min, and the initial lung uptake was cleared 2 h
later after injection. At 4 h after the injection, the distributions
of the intravenously injected PBSCs were 42.12% in spleen,
21.3% in liver and only 5.8% in lung (Kang et al., 2006).
In our experimental model, while many of the injected
BMSCs were in the lung, a substantial fraction of cells could
be found in the spleens and other organs of the recipient
mice 2 days after the injection. Several reasons might be
involved in this phenomenon. First, cell size has been
considered as a key factor in the pulmonary trapping
BMSCs. A single dose of 950 cGy irradiation might injure
the pulmonary capillary endothelium and increase the
pulmonary capillary filtration coefficient (Suzuki et al.,
1999), which may improve the passage of BMSCs. Second,
BMSC infusion with two injections had been used in our
experiments, which might result in an increased pulmonary
passage as compared to a single injection. Third, BMSCs in
the lethal aGvHD mice 2 days after the injection were likely
to further located into spleen by splenic inflammation
induced by aGvHD, like the intravenously injected neural
stem cells (NSCs) reaching the lymph nodes of mice with
intracerebral hemorrhage (ICH) or experimental autoim-
mune encephalomyelitis (EAE) (Lee et al., 2008; Einstein et
al., 2007).
Our results have also shown that the production of IL-6 and
PGE2 is pivotal in Notch-mediated immuno-suppression effects
of BMSCs on DCs. PGE2 inhibits T-cell activation and prolifer-
ation, and is synthesized by phospholipase A2 and COX from
arachidonic acid released from cellular membrane phospho-
lipids (Fitzpatrick and Soberman, 2001). Two isoforms of COX
have been found in many types of cells. COX-1 is expressed
constitutively in most mammalian tissues and is responsible for
housekeeping functions of PGs such as the regulation of gastric
acid secretion. COX-2, in contrast, is an inducible form and is
induced by a variety of cytokines during proinflammatory
responses. A complex of NIC and RBP-J has been shown to bind
to COX-2 promoter and elevate COX-2 expression in SC-M1 cells
(Yeh et al., 2009). This finding was consistent with our results
showing that the production of PGE2 was reduced significantly
in BMSCs when RPB-J gene was knocked out.
IL-6 plays amajor role in the regulation of immune response,
hematopoiesis, inflammation and oncogenesis (Kishimoto,
2010). A variety of transcription factors including AP1, C/EBPune responses through T-cell priming in vivo. (A) GFP+ DCs were
7BL/6 mice were immunized with OVA. In the first experiment,
, pulsed with OVA, and injected in the left hind footpads of the
GFP+ DCs were directly injected in the left hind footpads of the
ated). Mice were euthanized 3 days later, and the numbers of
cted as in (A), BrdU was administered by injection i.p. T-cells in
DCs migrating into draining lymph nodes were also examined.
s were examined by FACS. (H, I) The expressions of IFN-γ in CD3+
assay. BALB/C mice were immunized on the dorsal flank by
n day 7 and day 14 at the hind footpad by injecting the same
SCs (BMSC-DC), and injected i.p. on days −6, −4, 0, 3, and 6.
swelling was calculated as the thickness of the right footpads
left footpads. Bars = means ± SD. *, P b 0.05, n = 6.
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expression (Plaisance et al., 1997). The NF-κB family of
proteins is the key regulator of IL-6 gene transcription, and
conserved binding motifs for NF-κB were identified between −
73 and −64 bp upstream to the transcriptional start site of
the IL-6 promoter (Libermann and Baltimore, 1990). A RBP-J
protein-binding motif has been identified within the NF-κB-
binding sites, and RBP-J can bind to this region (Plaisance et
al., 1997; Palmieri et al., 1999). RBP-J has been shown as a
constitutive silencer of the IL-6 gene in the absence of NF-κB,
and functions as a modulator of NF-κB binding and trans-
activation, presumably by limiting the access of NF-κB to
DNA (Plaisance et al., 1997; Palmieri et al., 1999). However,
RBP-J-deficient murine macrophages produced less IL-6 upon
LPS stimulation (Wongchana and Palaga, 2012; Wang et al.,
2010b). Overexpression of NIC in RAW264.7 macrophages
resulted in significantly higher IL-6 expression than the control,
which could be completely abrogated by a NF-κB inhibitor
(Wongchana and Palaga, 2012). Consistently, in the current
study, IL-6 expression in BMSCs decreased significantly upon
RBP-J gene knockout (Osipo et al., 2008).
BMSCs interfere with DC differentiation, maturation and
function. IL-6 was initially thought as the main effector in the
inhibition of DC differentiation by BMSCs. Djouda et al.
reported that murine MSCs secreted high level of IL-6, which
down-regulates the expression of MHC II, CD40, and CD86 on
mature DCs and reduces T-cell proliferation. However, a
recent study showed the critical role of PGE2 in MSC-mediated
immuno-suppression (Glennie et al., 2005). Bouffi and col-
leagues found that IL-6 deficient MSCs exhibited the lowest
suppressive effect and did not significantly reduce the severity
of arthritis. In their experimental model, PGE2 expression was
reduced significantly in IL-6−/− MSCs, which indicated that the
immuno-regulatory function of MSCs was mainly attributed
to IL-6-dependent secretion of PGE2 (Bouffi et al., 2010).
However, an inhibitor of PGE2 can reverse the inhibition of DC
differentiation by BMSCs despite the presence of high amount
of IL-6 (Dong et al., 2010), suggesting that PGE2 may play a
more critical role than IL-6 (Wang et al., 2010a; Kumar et al.,
2012).
The Notch signaling pathway plays a pivotal role in
regulating cell differentiation during development. In recent
years, increasing evidence has been accumulated showing
that Notch signal modulates the direction of immune
responses by regulating the activation of various immune
cells. In the current study, we show that Notch signal is
required for BMSCs to exert their immuno-suppression roles.
These data provide further evidence that Notch signalFigure 6 IL-6 and PGE2 played the key roles in the regulation of D
were cultured alone or in combination with BM monocytes (BMM). A
measured by ELISA. In the (+ → −) group, BMM was removed after
another 5 days before IL-6 in the supernatant was measured. (B) To
analyzed by real-time PCR for relative level of IL-6 mRNA, with β-a
different genotypes were isolated by magnetic beads. Total cell lys
detecting the phosphorylated Stat3 (P-Stat3), Stat3, phosphorylated
monocytes were co-cultured with BMSCs of different genotypes. IL-6
After 9 days of culture, DCs were stimulated by LPS and collected by
MHC II were analyzed by FACS. MFI of these markers were compare
presence of BMM. The production of PGE2 was evaluated in the cultur
antibody was added into the medium. Bars = means ± SD. *, P b 0.0regulates immune regulatory effects of not only immune
cells, but also non-immune cells such as BMSCs.
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